ChiCTR2000032711 版本V1.1 版本创建时间2020/05/07 19:13:07 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000032711 

最近更新日期:

Date of Last Refreshed on:

2020-05-07 18:46:23 

注册时间:

Date of Registration:

1990-01-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

功能磁共振成像(fMRI)对鼻咽癌放疗后认知功能损害的早期评估

Public title:

Early detection of cognitive impairments after radiotherapy for nasopharyngeal carcinoma using functional MRI

注册题目简写:

English Acronym:

研究课题的正式科学名称:

功能磁共振成像(fMRI)对鼻咽癌放疗后认知功能损害的早期评估

Scientific title:

Early detection of cognitive impairments after radiotherapy for nasopharyngeal carcinoma using functional MRI

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

梁春雨 

研究负责人:

梁春雨 

Applicant:

Liang Chunyu 

Study leader:

Liang Chunyu 

申请注册联系人电话:

Applicant telephone:

18312563054

研究负责人电话:

Study leader's telephone:

18312563054

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Liangcy8@mail.hku-szh.org

研究负责人电子邮件:

Study leader's E-mail:

Liangcy8@mail.hku-szh.org

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

深圳市福田区海园一路1号

研究负责人通讯地址:

深圳市福田区海园一路1号

Applicant address:

1 Haiyuan 1st Road, Futian District, Shenzhen

Study leader's address:

1 Haiyuan 1st Road, Futian District, Shenzhen

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

香港大学深圳医院

Applicant's institution:

Shenzhen Hospital of the University of Hong Kong

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦[2019]368

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

香港大学深圳医院伦理委员会

Name of the ethic committee:

Ethics Committee of Hong Kong University Shenzhen hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2020-01-17 00:00:00

伦理委员会联系人:

王静贤

Contact Name of the ethic committee:

Wang Jingxian

伦理委员会联系地址:

深圳市福田区海园一路1号香港大学深圳医院科教管理楼

Contact Address of the ethic committee:

Science and education management building of Hong Kong University Shenzhen hospital,1 Haiyuan 1st Road, Futian District, Shenzhen

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

香港大学深圳医院

Primary sponsor:

Shenzhen Hospital of the University of Hong Kong

研究实施负责(组长)单位地址:

深圳市福田区海园一路1号

Primary sponsor's address:

1 Haiyuan 1st Road, Futian District, Shenzhen

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

香港大学深圳医院

具体地址:

深圳市福田区海园一路1号

Institution
hospital:

Shenzhen Hospital of the University of Hong Kong

Address:

1 1st Haiyuan Road, Futian District, Shenzhen

经费或物资来源:

香港大学深圳医院”科研培育计划”青年项目(13万元人民币)

Source(s) of funding:

Youth project of

Target disease:

nasopharyngeal carcinoma

Target disease code:

研究类型:

病因学/相关因素研究

Study type:

Cause/Relative factors study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

放射治疗是治疗鼻咽癌的最主要和最有效方法,为达到肿瘤控制的目的,周围邻近正常脑组织特别是颞叶常常有一定受量,有可能导致放射性脑损伤,颞叶特别是海马结构、海马旁回,是边缘系统的重要组成结构,参与学习、记忆等重要认知功能。 因此,鼻咽癌患者放疗可导致学习、记忆等神经认知功能损伤,严重影响患者放疗后的生活质量。 鼻咽癌患者放疗后的认知功能损害症状较隐蔽,早期不易觉察,且放疗后的认知功能障碍与颞叶受照射(或与肿瘤照射剂量学)之间的关系尚不明确,随着放疗技术的日渐精进,鼻咽癌放疗后患者的生存期越来越长,因此,这些患者的生活质量也应该受到重视。但是,目前调强放疗对鼻咽癌患者认知功能影响的研究较少。 本研究拟运用功能磁共振(fMRI)结合智力量表,主要对鼻咽癌患者放疗后认知功能的损伤进行早期发现,并观察认知功能损害与颞叶受照射计量之间是否有相关性,为预防放疗不良反应及改善放疗后的生命质量提供基础。  

Objectives of Study:

Radiotherapy (RT) is the most important treatment method for nasopharyngeal carcinoma (NPC). However,in order to cure NPC, nearby normal brain tissues, especially the bilateral temporal lobes, often receive unnecessary radiation. The temporal lobes, expecilly the hippocampus and the parahippocampal gyrus, are important structures of limbic system, which play important role in cognitive function. Hence, patients with NPC treated by RT may occur cognitive impairments, which significantly impair the quality of life. The symptoms of cognitive dysfunction induced by RT in NPC patients are not easy for early detection. Moreover, the relationship between the cognitive impairment induced by RT and the radiation dose is still unclear. With the development of RT techniques, the NPC patients live longer and longer after RT treatment, therefore, doctors should not only pay attention to the tumor treatment but should also take note of the cognitive impairments of patients. However, at the moment, studies major on this field are rare. Therefore, our studies plan to use fMRI together with intelligence scale to detect cognitive impairments after RT treatment, and observe whether there is relationship between the cognitive impairment and the radiation dose. We are expecting the studies will give help to preventing side effects of RT and improving the quality of life after RT for NPC patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1).第一组病例(确诊鼻咽癌患者接受放射治疗前)入组标准:
①病理证实的鼻咽鳞癌或腺癌的、待放疗的初诊患者;无鼻咽癌颅内侵犯;颅内无肿瘤性病变和血管性病变;无心脏病、糖尿病;常规MR平扫及增强扫描序列颅内无明显异常信号。
②年龄:≥18岁;
③一般状态良好,能配合检查,良好的肝肾功能:血清胆红素<1.5?ULN(正常参考值上限),AST(谷草转氨酶)及ALT(谷丙转氨酶)< 2.5?ULN,血清肌酐清除率≥50ml/分。
④提供知情同意。
(2).第二组病例(确诊鼻咽癌患者接受放射治疗后)入组标准:
①病理证实的鼻咽鳞癌或腺癌的鼻咽癌患者,肿瘤分期与第一组患者匹配,确诊后均在我院行三维适形或调强放疗(总剂量为 66~74 Gy,分割次数为30~35次)。无鼻咽癌颅内侵犯;颅内无肿瘤性病变和血管性病变;无心脏病、糖尿病;常规MR平扫及增强扫描序列颅内无明显异常信号。
②年龄:≥18岁;
③一般状态良好,能配合检查,良好的肝肾功能:血清胆红素<1.5?ULN(正常参考值上限),AST(谷草转氨酶)及ALT(谷丙转氨酶)< 2.5?ULN,血清肌酐清除率≥50ml/分。
④提供知情同意。
(3).第三组病例(对照组)入组标准:
①与第一组年龄、性别、文化程度相匹配的正常人作为对照。MRI扫描确认颅内无肿瘤性病变和血管性病变;无心脏病、糖尿病;常规MR平扫及增强扫描序列颅内无明显异常信号。
②年龄:≥18岁;
③一般状态良好,能配合检查,良好的肝肾功能:血清胆红素<1.5?ULN(正常参考值上限),AST(谷草转氨酶)及ALT(谷丙转氨酶)< 2.5?ULN,血清肌酐清除率≥50ml/分。
④提供知情同意。

Inclusion criteria

Group 1: patients of nasopharyngeal carcinoma,before radiotherapy
1、Initial diagnosis of nasopharyngeal carcinoma confirmed by pathology, no intracranial invasion. There is no tumor or vascular disease in the brain, no heart disease or diabete. There is no obvious abnormal signal in conventional MR plain scan and enhanced scan sequence.
2、Over 18 years old.
3、Generally in good condition, able to cooperate. Good liver and kidney function.
4、Able to provide informed consent.

Group 2: the same patients with group 1,after radiotherapy
1、patients after radiotherapy in our hospital. There is no tumor or vascular disease in the brain, no heart disease or diabete. There is no obvious abnormal signal in conventional MR plain scan and enhanced scan sequence.
2、 Over 18 years old.
3、Generally in good condition, able to cooperate. Good liver and kidney function.
4、Able to provide informed consent.

Group 3: the control group
1、Age, gender and education matched normal people as control. There is no tumor or vascular disease in the brain, no heart disease or diabete. There is no obvious abnormal signal in conventional MR plain scan and enhanced scan sequence.
2、Over 18 years old.
3、Generally in good condition, able to cooperate. Good liver and kidney function.
4、Able to provide informed consent.

排除标准:

①误纳误入者;
②明确不符合实验方案或违背试验方案者;有幽闭恐惧症无法行颅脑MRI检查的受试者;
③正在参加其他临床试验的受试者或30天内参加其他临床试验者;
④具有严重心、肺、肝、肾等疾病,言语或手部运动受限,严重听力或视力障碍,影像学报告脑萎缩,病史中有过其他颅脑疾病,精神活性物质依赖或其他精神疾病的受试者。

Exclusion criteria:

1、 Misinducted subjects.
2、 Those who do not conform to the test plan or violate the test plan. Subjects with claustrophobia who could not be examined by brain MRI.
3、 Subjects who are participating in or have recently participated in other clinical trials.
4、 Those who with Serious other diseases. Subjects with Limited speech or hand movement, or with Severe hearing or visual impairment. Subjects who have had other craniocerebral diseases, psychoactive substance dependence or other mental disorders.

研究实施时间:

Study execute time:

From 2019-07-01 00:00:00 To 2022-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-06-01 00:00:00 To 2020-12-31 00:00:00  

干预措施:

Interventions:

组别:

确诊鼻咽癌患者接受放射治疗前

样本量:

15

Group:

before radiotherapy group

Sample size:

干预措施:

Nil

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

确诊鼻咽癌患者接受放射治疗后

样本量:

15

Group:

after the confirmed NPC patients received radiotherapy group

Sample size:

干预措施:

Nil

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

对照组

样本量:

15

Group:

Control group

Sample size:

干预措施:

Nil

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China 

Province:

Guangdong 

City:

 

单位(医院):

香港大学深圳医院 

单位级别:

三甲医院 

Institution
hospital:

Shenzhen Hospital of the University of Hong Kong

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

磁共振信号

指标类型:

主要指标

Outcome:

MR signal

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

病例对照研究,符合纳入标准的患者进入病例中,病例组又分为放疗前组和放疗后组,相匹配的志愿者为对照组

Randomization Procedure (please state who generates the random number sequence and by what method):

case-control study

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始数据使用光盘保存,实验人员共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data is saved on CD and shared by the experimenters.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

收集入组受试者的临床资料包括:年龄、TMN分期、病理类型、放疗完成周期数、总治疗时间。使用病例记录表(CRF)记录。 记录患者及对照组志愿者的fMRI扫描数据,使用光盘从磁共振机器上刻录保存数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Collect the clinical data of the enrolled subjects,use case record form (CRF)to record.FMRI data of patients and control group volunteers were recorded on CD.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-05-07 18:45:59